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Background. Late transient neonatal hypocalcemia with hyperphosphatemia is potentially life-threatening. The use of 1.25
dihydroxycholecalciferol in the management of neonatal hypocalcemia is unexplored. Objective. We hypothesized adding 1.25
dihydroxycholecalciferol to intravenous continuous calcium infusion (CaI) will achieve accelerated correction of hypocalcemia.
Design/Methods. A controlled double-blind randomized placebo group was organized to compare the addition of 1.25
dihydroxycholecalciferol to CaI in 3–14 day old neonates presenting with hypocalcemia, hyperphosphatemia and seizures. Ionized
calcium and phosphorus were measured to adjust CaI and maintain eucalcemia. Time to resolution of hypocalcemia was deﬁned
as time from starting CaI to the ﬁrst ionized calcium of ≥1.1mmol/L. CaI was discontinued when ionized calcium levels were
≥1.1mmol/L on two measurements and the infant tolerated feeds. Results. Fourteen neonates were studied without statistical
diﬀerence between groups. Time to correction of hypocalcemia for 1,25 dihydroxycholecalciferol versus placebo was 7.2 ± 1.9
versus 11.5 ± 3.4h o u r sr e s p e c t i v e l y(p = .26). The duration of CaI was 15.0 ± 1.5v e r s u s2 4 .8 ± 4.4h o u r sr e s p e c t i v e l y(p = .012).
Conclusions.Theadditionof1.25 dihydroxycholecalciferol tostandardCaItherapyreduced thedurationofCaI,butdidnotreduce
the time to correct hypocalcemia in neonates with late transient hypocalcemia.
1.Introduction
Late transient neonatal hypocalcemia with hyperphos-
phatemia is a potentially life-threatening condition ﬁrst
reported in the 1930s. The condition presents between days
of life 3–14, typically with tetanic seizures in a previously
healthy term neonate [1]. This condition is rarely seen in
breast-fed infants and is believed to be associated with a
high phosphate load in the formula [2, 3]. Introduction
of formulas with lower phosphate loads has not eliminated
the occurrence of transient neonatal hypocalcemia [1, 4–
8]. This condition continues to be seen with a frequency
of 30/10,000 among formula-fed neonates [2, 8]. The
standard treatment of symptomatic neonatal hypocalcemia
is intravenous calcium infusion [8, 9]. Extravasation of
intravenous calcium can result in severe tissue necrosis [3].
IV inﬁltration rates among neonates vary from 57% to 70%
and extravasation occurs in 11% to 23% of reported cases
[10–12]. The most common cause of IV inﬁltration is total
parenteral nutrition (76%) and calcium (72%) [11, 12].
In addition, intravenous calcium has also been associated
with cardiac arrhythmias, notably bradycardia. The use of
1,25-Dihydroxyvitamin D [1,25(OH)2Vitamin D] in the
management of transient hypocalcemia is less clear [3, 9].
1,25(OH)2 Vitamin D might reduce the time of correction
of hypocalcemia and the duration of intravenous calcium
administrationbystimulatingcalciummobilizationfromthe
bones, reducing renal proximal tubular excretion of calcium,
and promoting absorption of calcium from the duodenum
during hypocalcemia [9, 13, 14].
To our knowledge there are no controlled studies that
have evaluated the eﬀect of adding 1,25(OH)2 Vitamin
D to intravenous continuous calcium infusion for late
transient neonatal hypocalcemia. We hypothesized that the2 International Journal of Pediatric Endocrinology
addition of 1,25(OH)2 Vitamin D to standard intravenous
continuous calcium infusion would achieve more rapid
resolution of hypocalcemia and shorten the duration of
intravenous continuous calcium infusion when compared
with intravenous continuous calcium infusion alone.
2. Study Design
Following approval by the Baylor College of Medicine’s
Institutional Review Board, subjects were prospectively
enrolled in this double-blind, randomized clinical study.
Patients were randomized by pharmacy staﬀ and they
were the only ones aware of what therapy infants were
receiving. Term infants 3–14 days old weighing ≥2000
grams were eligible for the study if they presented with
hypocalcemia (ionized calcium ≤1.0mmol/L or total cal-
cium ≤8.0mg/dL), hyperphosphatemia (phosphorus ≥ 6.0
mg/dL), and seizures. All infants had to demonstrate a
normal cardiothymic silhouette on chest radiograph and
have no known congenital anomalies. Recruitment occurred
at Texas Children’s Hospital between February 2004 through
April 2005. Patients were excluded if there was any history
of anticonvulsant use, subsequent diagnosis of DiGeorge
Syndrome by FISH, or conﬁrmed sepsis. Infants were also
excluded if the mother had diabetes mellitus or a known
disorder of calcium metabolism.
Intravenous calcium levels and other baseline laboratory
studies were collected once hypocalcemia was suspected.
Informed consent was obtained within 6 hours of admis-
sion. Infants were randomized to receive 0.25 micrograms
of 1,25(OH)2 Vitamin D or placebo (saline) daily after
intravenous continuous calcium infusion was initiated. Time
of correction of hypocalcemia was deﬁned as the time from
initiation of intravenous continuous calcium infusion to
the ﬁrst measured ionized calcium level of ≥1.1mmol/L.
Duration of intravenous continuous calcium infusion was
deﬁnedasthetimefrominitiationofintravenouscontinuous
calcium infusion to the time when intravenous continuous
calcium infusion was discontinued.
The evaluation, titration, and dosing of intravenous con-
tinuous calcium infusion were based on the clinical protocol
described below. The following baseline diagnostic studies
were collected to evaluate the etiology of hypocalcemia:
total calcium, ionized calcium, serum phosphorus, serum
magnesium, intact parathyroid hormone, 25(OH) Vitamin
D, 1,25(OH)2Vitamin D, FISH for DiGeorge Syndrome and
AP chest radiograph. Maternal etiologies of hypocalcemia
included diabetes, vitamin D deﬁciency, and hyperparathy-
roidism. These were evaluated by measuring maternal
HbA1C, 25(OH) Vitamin D, 1,25(OH)2 Vitamin D, intact
parathyroid hormone, serum ionized calcium, phosphorus
and magnesium levels. After all diagnostic studies were
collected, a bolus of 10 mg of elemental calcium/kg was
administered intravenously over 30 minutes. Infants were
then started on an intravenous continuous calcium infusion
of 100mg elemental calcium/kg/day. Ionized serum calcium
and phosphorus levels were obtained every 4–6 hours.
The intravenous continuous calcium infusion was titrated
to maintain ionized serum calcium levels between 1.1-
1.2mmol/L. Hypomagnesemia was corrected if serum mag-
nesiumwas ≤1.5mg/dL.Ifserumionizedcalciumlevelswere
≥1.2mmol/L, the intravenous continuous calcium infusion
was reduced using the same algorithm in both groups.
Infants were started on Similac PM 60/40 (a low phosphate
load formula) or breast milk when ionized calcium was
≥1.1mmol/L and there was no seizure activity within the
past 2 hours. Oral calcium was started once infants tolerated
their ﬁrst feeding. Initial dose of oral calcium was 25mg ele-
mentalcalcium/kg/daygivenin4dailydoses (every6hours).
Two hours after the ﬁrst oral calcium dose was administered,
the intravenous continuous calcium infusion was reduced
by an amount corresponding to the oral calcium dose. If
the ionized calcium level was ≥1.1mmol/L on two separate
measurements assuring that calcium level had consistently
remained stable and the infant tolerated feeds, infants
were switched from intravenous to oral calcium dosing.
Intravenous continuous calcium infusion was discontinued
2 hours after the switch to full oral dosing. Serum ionized
calcium, phosphorus, and total calcium were checked three
hours after the intravenous continuous calcium infusion
was discontinued. Once intravenous continuous calcium
infusion was stopped, serum calcium and phosphorus levels
were obtained every 12 hours and 1,25(OH)2 Vitamin D or
placebo daily was changed from intravenous to oral delivery.
3.StatisticalAnalysis
All data in the results section are expressed as mean ±
standard error. Analysis of covariance (ANCOVA) was used
to analyze time of correction of hypocalcemia and time to
discontinue intravenous continuous calcium infusion. Initial
ionized calcium was covariate in the analysis. Students t-test
was used to analyze the diﬀerence in weight, age at seizures,
baseline laboratories and maternal laboratories.
4. Results
Fourteen formula-fed neonates were studied [7 receiving
placebo, 7 receiving 1,25(OH)2 Vitamin D]. Four infants
received less than 4oz (120cc) a day of expressed breast
milk. The formulas used included Enfamil LIPIL with Iron
(9 infants), Similac Advance (3 infants), Enfamil LactoFree
LIPIL (1 infant), and Similac Isomil Advance (1 infant). Ten
infants were Hispanic (8 male/2 female) and 4 Caucasian (all
males). All results are expressed as mean ± SEM. Baseline
data and laboratory tests are summarized in Table 1.
There was no statistical diﬀerence between the placebo
and 1,25(OH)2 Vitamin D group with regard to age at
ﬁrst seizure, age of admission, weight, and all baseline
tests except phosphorus (Table 1). The placebo group had
a higher initial serum phosphorus level [P = .03; unpaired
t-test when compared to 1,25(OH)2 Vitamin D group].
All maternal diagnostic tests were normal, except 25(OH)
Vitamin D which was low (Table 1). 1,25(OH)2 Vitamin
D was initiated 4.8 ± 0.5 hours after starting intravenous
continuous calcium infusion due to processing of the studyInternational Journal of Pediatric Endocrinology 3
Table 1: Demographics and baseline laboratory tests by treatment group.
(Units) BirthWeight
(kg) Age (days) Gender
(M/F)
Ethnicity
(Hispanic/
Caucasian)
Ionized
Calcium
(mmol/L)
Phosphorus
(mg/dL)
Mg
(mg/dl)
Intact
PTH
(pg/mL)
25(OH)
Vitamin D
(ng/mL)
1,25(OH)2
Vitamin D
(pg/mL)
Placebo 4.06 ± 0.30 5.4 ± 0.5 6/1 6/1 0.86 ± 0.04 10.5 ± 0.3∗ 1.3 ± 0.1 26.0 ± 4.0 14.2 ± 2.8 159.4 ± 31.1
1,25(OH2)
Vitamin D 3.73 ± 0.21 6.3 ± 0.4 6/1 4/3 0.88 ± 0.02 9.4 ± 0.2 1.2 ± 0.1 31.6 ± 4.7 15.1 ± 2.8 140.3 ± 10.7
Mean 3.91 ± 0.16 5.9 ± 0.3 0.87 ± 0.02 10.0 ± 0.2 1.2 ± 0.1 30.0 ± 3.0 15.0 ± 2.0 148.0 ± 14.0
Mother
HgA1C
(%) 5.2 ±
0.4
Total
Calcium
(mg/dl)
9.35 ± 0.35
3.6 ± 0.2 3.0 ± 0.8 65.2 ±
16.3 15.3 ± 4.0 36.8 ± 5.0
∗P = .03; t-test when compared to 1,25(OH)2 Vitamin D group Conversion factors:
Phosphorus mmol/L = mg/dL × 0.32.
Magnesium mmol/L = mg/dL × 0.5.
∗
Correction of
hypocalcemia
Duration of
IV calcium
1,25(OH)2 vitamin D
Placebo
∗P = .012; covariate analysis with initial
iCa when compared to placebo group
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Figure 1: Time to correct hypocalcemia and duration of intra-
venous calcium infusion by treatment group. (1) Criteria for
correction of hypocalcemia: (i) ionized Ca ≥ 1.1mmol/L, (ii)
seizure free for 2 hours. (2) Criteria for discontinuation of IV
calcium: (i) ionized Ca ≥ 1.1mmol/L × 2, (ii) tolerating feeds.
and preparing medication in pharmacy. The time of correc-
tion of hypocalcemia for 1,25(OH)2 Vitamin D group versus
placebo was 7.2 ± 1.9 versus 11.5 ± 3.4 hours, respectively,
(P = .26). Duration of intravenous continuous calcium
infusion was 15.0 ± 1.5 versus 24.8 ± 4.4 hours, respectively
(P = .012) (Figure 1). Intravenous continuous calcium
infusion was not restarted in any of the neonates once it
was discontinued. No tissue necrosis or other complications
occurred in any of the neonates during the study.
5. Discussion
Neonatal hypocalcemia is clinically divided into early and
late presentation. Early neonatal hypocalcemia is deﬁned
as occurring in the ﬁrst 48 hours of life. The diﬀerential
diagnosis includes prematurity, intrauterine growth retarda-
tion, and birth asphyxia [3, 9]. Maternal factors including
gestationaldiabetes,vitaminDdeﬁciency,andhyperparathy-
roidism can also cause early neonatal hypocalcemia [3, 9,
15–17]. Late neonatal hypocalcemia is generally deﬁned as
hypocalcemia presenting with seizures after the 3rd day
of life [18–22]. The diﬀerential diagnosis for late neona-
tal hypocalcemia includes high phosphate load formulas,
hypomagnesemia, hypoparathyroidism (including DiGeorge
Syndrome), disorders of vitamin D metabolism, bicarbonate
infusion, citrate load in transfused blood, lipid infusions,
maternal hyperparathyroidism, or any combination of the
above [1–3, 9, 20–22]. Our infants were all healthy term
infants fed high phosphate formula presenting at the end of
the ﬁrst week of life with hypocalcemia, hyperphosphatemia,
hypomagnesemia, and seizures. Almost all reported cases of
late transient neonatal hypocalcemia are seen in formula-fed
infants(30/10000comparedto1/10000inbreast-fedinfants)
[8]. Some authors speculate that the high phosphate load in
commercially available formulas combined with immature
renal phosphorus excretion and immaturity of the parathy-
roid hormone response results in a “relative hypoparathy-
roidism” which is most likely to occur in the ﬁrst 3 weeks
of life resulting in neonatal hypocalcemia [1, 2, 4–8, 23, 24].
Late transient neonatal hypocalcemia continues to be
reported despite recent reduction in phosphate load in the
commercially available formulas [1, 2, 4, 5, 7, 8, 23]. Infants
presenting with hypocalcemic seizures require intravenous
calciumtorapidlycorrecthypocalcemia[3,9].Extravasation
ofintravenouscalciumcanresultinseveretissuenecrosis[3].
IV inﬁltration rates among neonates vary from 57% to 70%
and extravasation occurs in 11% to 23% of reported cases
[10–12]. The most common cause of IV inﬁltration is total
parenteral nutrition (76%) and calcium (72%) [11, 12].
We postulated that the use of 1,25(OH)2 Vitamin D in
our study population would reduce the time of correction of
hypocalcemia. We found that the time to correct hypocal-
cemia was not statistically diﬀerent between the placebo
and 1,25(OH)2 Vitamin D treated groups. Due to the delay
processing the study and preparing medication in pharmacy,
1,25(OH)2 Vitamin D was initiated 4.8 ± 0.5 hours after4 International Journal of Pediatric Endocrinology
starting intravenous continuous calcium infusion. Earlier
administration of 1,25(OH)2 Vitamin D might have further
reduced the time of resolution of hypocalcemia. The onset of
action of 1,25(OH)2 Vitamin D is approximately 4–6 hours.
On average, hypocalcemia was corrected 7.2 ± 1.9 hours
after intravenous continuous calcium infusion was started
and 4.5 hours after 1,25(OH)2 Vitamin D was given. There
was probably not enough time for the 1,25(OH)2 Vitamin D
to mobilize calcium from the bone. The high dose of intra-
venous continuous calcium used may also have obscured the
eﬀect of 1,25(OH)2 Vitamin D. The study might have also
been underpowered (83%) due to small sample size.
Once calcium was corrected, 1,25(OH)2 Vitamin D
helped maintaining the ionized calcium concentration above
1.1mmol/L. This allowed the intravenous continuous cal-
cium infusion to be discontinued 10 hours sooner than in
the control group. This 10-hour time diﬀerence may reﬂect
the time it takes for 1,25(OH)2 Vitamin D to exert its
full eﬀect on calcium metabolism. This eﬀect is mediated
by 1,25(OH)2 Vitamin D stimulating calcium mobilization
fromthebonessincepromotingcalciumabsorptionfromthe
duodenum and proximal small intestine is mostly vitamin
D independent in neonates [9, 14]. Reduction of renal
proximal tubular excretion of calcium would also be an
expected mechanism of action by 1,25(OH)2 Vitamin D
duringhypocalcemiaalongwithstimulationofnon-genomic
pathways involving paracellular calcium absorption due to
upregulation of Vitamin D receptor and calcium-sensing
receptor [10, 13, 25].
In conclusion, the addition of 1,25(OH)2Vitamin D to
standard intravenous continuous calcium infusion reduced
theinfusiondurationneededtoeﬀectivelytreatlatetransient
neonatal hypocalcemia. A shorter duration of intravenous
continuous calcium infusion may reduce the risk of compli-
cations associated with intravenous calcium infusion, such
as tissue necrosis due to extravasations and could translate to
reduced medical cost.
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